Interactions between lunesta(eszopiclone) and Anturane (sulfinpyrazone)
sulfinpyrazone and eszopiclone (Moderate Drug-Drug)
MONITOR: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of zopiclone, which is a substrate of the isoenzyme. According to product labeling, zopiclone systemic exposure (AUC) was decreased 80% by concomitant use of rifampin, a potent inducer of CYP450 3A4. A similar effect would be expected with eszopiclone, the S-enantiomer of zopiclone. Pharmacodynamically, many CYP450 3A4 inducers such as barbiturates and anticonvulsants have CNS-depressant effects, which may be additive with those of zopiclone and eszopiclone.
MANAGEMENT: Pharmacologic response to zopiclone and eszopiclone should be monitored more closely whenever a CYP450 3A4 inducer is added to or withdrawn from therapy, and the hypnotic dosage adjusted if necessary.
